Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BalanceD-CKD
2026-526114-90-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Balcinrenone + dapagliflozin with Dapagliflozin + placebo (2 arms). Primary endpoints: Composite renal and cardiovascular outcome and First occurrence of composite event. Planned start Nov 2026; status: authorised.
02
Drugs
balcinrenonedapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2026-526114-90-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526114-90-00.